期刊文献+

JAK ERK1/2两通路交互作用干预对缺血再灌注心肌p-STAT3和肿瘤坏死因子-α表达的影响 被引量:2

JAK and ERK1/2:how intervention on these two pathways affects myocardial p-STAT3 and TNF-α expression in ischemia-reperfusion
下载PDF
导出
摘要 目的研究Janus激酶/信号转导和转录激活子(JAK/STAT)通路和细胞外信号调节激酶1/2(ERK1/2)信号转导通路交互作用对缺血再灌注损伤所致大鼠心肌组织p-STAT3及肿瘤坏死因子(TNF)-α蛋白含量的影响。方法采用Langendorff离体工作心脏灌注模型,大鼠随机分为健康对照组、缺血再灌注组、JAK抑制剂组、ERK1/2抑制剂组、JAK、ERK1/2两通路交互作用组。采用Western印迹法测定心肌p-STAT3蛋白含量,酶联免疫吸附测定法(ELISA)检测试剂盒检测TNF-α蛋白含量。结果与健康对照组相比,心肌组织p-STAT3含量及TNF-α蛋白含量在缺血再灌注组显著升高(P<0.01)。JAK抑制剂组及交互作用组处理后p-STAT3蛋白含量、TNF-α蛋白含量与缺血再灌注组相比明显下降(P<0.01,P<0.05);且2组间比较差异有统计学意义(P<0.05)。而ERK1/2抑制剂组处理后p-STAT3、TNF-α蛋白含量与缺血再灌注组差异无统计学意义(P>0.05)。结论缺血再灌注心肌损伤可使p-STAT3蛋白含量、TNF-α蛋白含量明显升高;抑制JAK/STAT信号转导通路可使其下游蛋白p-STAT3含量及TNF-α蛋白含量明显降低,且同时抑制ERK1/2信号通路对其心肌保护有明显抑制作用。 Objective To investigate how the interaction between Janus kinase / signal transducer and activator of transcription (JAK/STAT) pathway and extracellular signal-regulated kinase 1/2 (ERK1/2) signal transduction pathway affects myocardial p-STAT3 and TNF-α protein contents in isehemia-reperfusion. Methods The Langendorff isolated myocardial ischemia-perfusion model was applied. Forty SD rats were randomly divided into normal control group, ischemia-reperfusion group, JAK inhibitor group, ERK1/2 inhibitor group, and JAK-ERK1/2 interaction group. Myocardial p-STAT3 protein content was determined with Western blotting and myocardial TNF-α protein content with ELISA. Results Compared with normal eontrol group, the myocardial p-STAT3 level and TNF-α protein content in the ischemia-reperfusion group was significantly higher (P〈0.01). The elevated p-STAT3 level and TNF-α protein content were evidently lowered in JAK inhibitor group and the interaction group compared with the ischemia-reperfusion group (P〈0.01, P〈0.05) and also showed statistical difference when comparison was made between the two groups (P〈0.05), whereas the p-STAT3 and TNF-α protein in ERK1/2 inhibitor group appeared comparable to the ischemiareperfnsion group (P〉0.05). Conclusion Myocardial ischemia-reperfusion injury may result in obvious elevation in p- STAT3 and TNF-α protein contents. Inhibition of JAK / STAT signal transduction pathway may significantly reduce p- STAT3 and TNF-α protein content, and at the same time inhibit ERKI/2 signaling pathway in favor of myocardial protection.
作者 徐睆 马捷
出处 《中国药物与临床》 CAS 2010年第1期17-20,共4页 Chinese Remedies & Clinics
基金 山西省回国留学人员科研资助项目(96)
关键词 再灌注损伤 心肌 肿瘤坏死因子Α P-STAT3 Reperfusion injury Myocardium Tumor necrosis factor-alpha P-STAT3
  • 相关文献

参考文献9

  • 1Kisseleva T, Braunstein J, Bhattacharya S,et al. Signaling through the JAK/STAT pathway,recent advances and future challenges. Gene,2002,285( 1-2): 1-24.
  • 2Barsotti A, Di-Napoli P, Spina R,et al. MK-954 (losartan potassium) exerts endothelial protective effects against reperfusion injury: evidence of an eNOS mRNA overexpression after global ischemia. Atherosclerosis, 2001,155 ( 1 ) : 53-59.
  • 3Aller MA,Arias JL, Nava MP,et al. Osttraumatic inflammation is a complex response based on the pathological expression of the nervous,immune,and endocrine functional systems. Exp Biol Med(Maywood), 2004,229(2):170-181.
  • 4Levy DE,Damell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol,2002,3(9):651-662.
  • 5Kreb DL,Hihon DJ. SOCS proteins: negative regulators of cytokine signal. Stem Cells,2001( 19): 378-387.
  • 6许建忠,施仲伟.心肌缺血与左室舒张功能异常[J].国外医学(心血管疾病分册),2005,32(1):31-33. 被引量:4
  • 7Fichtlscherer S,Rossig L,Breuer S,et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation, 2001,104 ( 25 ) :3023 -3025.
  • 8Me|dram D. Tumor necrosis factor in the heart.Am J Physiol, 1998,274 (3Pt2) :577-595.
  • 9Held TK,Weihua X,Yuan L,et al. Gamma interferon augments macrophage activation by lipopolysaccharide by two distinct mechanisms,at the signal transduction level and via an autocrine mechanism involving tumor necrosis factor alpha and interleukin- 1. Infect Immun, 1999,67( 1 ):206.

二级参考文献14

  • 1Gao WD, Atar D, Backx Ph,et al. Circ Res,1995;76(6):1036~1048.
  • 2Varma N,Morgan JP, Apstein CS. Am J Physiol Heart Circ Physiol, 2003; 284 (3): H758 ~ H771.
  • 3Manolas J,Chrysochoou C,Kastelanos S, et al. Clin Cardiol,2001;24(11) :735~743.
  • 4Varma N, Eberli FR, Apstein CS. Circulation, 2000; 101(18): 2185~2192.
  • 5Leather HA, De Wolff MH, Wouters PF. Eur J Anaesthesiol,2003; 20(3): 191~ 198.
  • 6Najos Valencia O,Cain P,Case C,et al. Am Heart J,2002;144(3) :516~523.
  • 7Wada Y,Murata K, Kimura K,et al. J Am Soc Echocardiogr,2003 ; 16(4) :309~317..
  • 8Moller JE, Hillis GS, Oh JK, et al. Circulation, 2003; 107(17): 2 207~2 212.
  • 9Moller JE,Egstrup K,Kober L,et al. Am Heart J,2003;145(1) :147~153..
  • 10Klisiewicz A, Michalek P, Witkowski A, et al. Przegl Lek,2002; 59(8): 655~657..

共引文献3

同被引文献6

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部